Strong Performance in Aflac Japan
Aflac Japan reported a 23.2% year-over-year sales increase, driven by a 53% increase in cancer insurance sales, led by the new Miraito product.
Capital Return to Shareholders
Aflac Incorporated deployed $829 million in capital to repurchase 7.9 million shares and paid dividends of $312 million, delivering $1.1 billion back to shareholders in Q2 2025.
Persistency and Premium Growth in Aflac U.S.
Aflac U.S. reported a 2.7% year-over-year increase in new sales, maintaining a strong premium persistency of 79.2% and a 3.4% increase in net earned premium.
Strong Capital Position
Aflac's combined RBC is estimated to be greater than 600%. The company holds a solid capital position with high return on capital and low cost of capital.